A Phase 1 Study of the Oral TRK Inhibitor LOXO-101 in Adult Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Larotrectinib (Primary)
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Loxo Oncology
- 04 Dec 2017 Planned number of patients changed from 108 to 90.
- 18 Oct 2017 Top-line results from Independent Review Committee Assessment of Larotrectinib dataset were presented in a Loxo Oncology media release.
- 06 Jun 2017 Results (data cut off: 31 Jan 2017, n=55) from NCT02122913, NCT02637687 and NCT02576431 studies, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History